STOCK TITAN

CON (NYSE: CON) insider files to sell 130,000 shares via UBS Financial

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CON filed a Form 144 notice reporting an intended sale of 130,000 shares of Common Stock with an aggregate offering price of $3,250,000.00. The filing lists shares outstanding of 127,961,780 as of 05/08/2026 and shows prior private purchase lots on 04/29/2005, 06/02/2005, and 11/08/2005.

Positive

  • None.

Negative

  • None.
Shares proposed for sale 130,000 shares Form 144 reported amount
Aggregate offering price $3,250,000.00 Form 144 reported aggregate price
Shares outstanding 127,961,780 shares as of 05/08/2026
Prior lot — 06/02/2005 72,132 shares private purchase of stock
Prior lot — 11/08/2005 33,624 shares private purchase of stock
Prior lot — 04/29/2005 24,244 shares private purchase of stock
Form 144 regulatory
"Filer Information | 144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Aggregate offering price financial
"130000 | 3250000.00 | 127961780 | 05/08/2026"
The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.
Private purchase of stock financial
"06/02/2005 | Private purchase of stock"

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does CON's Form 144 report?

CON's Form 144 reports a proposed sale of 130,000 shares of Common Stock for an aggregate price of $3,250,000.00. The filing also cites outstanding shares of 127,961,780 as of 05/08/2026 and prior private purchase lots from 2005.

Who is listed as the broker or intermediary on the Form 144 for CON?

The filing lists UBS Financial Services Inc., Eleven Madison Avenue as the broker/intermediary. The Form 144 excerpt associates UBS with the proposed transaction but does not disclose execution timing or sale method details.

What historical purchase lots are shown in the CON Form 144?

The Form 144 shows private purchase lots: 24,244 shares on 04/29/2005, 72,132 shares on 06/02/2005, and 33,624 shares on 11/08/2005. These dates and lot sizes are provided as the basis for the resale reporting.

Does the Form 144 state when the sales will occur?

The excerpt does not specify execution dates for the proposed sale. It reports the quantity (130,000 shares) and aggregate price ($3,250,000.00) but does not provide timing or confirm completed transactions.

How does the Form 144 relate to shares outstanding for CON?

The filing lists 127,961,780 shares outstanding as of 05/08/2026. That figure is presented in the excerpt as a baseline company share count; the filing does not state comparative dilution implications or post-sale outstanding figures.